The aurora A selective inhibitor LY3295668 (Erbumine) is currently being tested in a phase I clinical trial (NCT03955939) as a single agent and combined with ET in ER+/HER2− ABC patients previously treated with CDK4/6i-based therapy. Here, CDK4 is linked to aneurysmal bone cyst.